BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 30, 2024
See today's BioWorld
Home
» Pfizer bets on CD47 blockade in cancer with $2.3B Trillium bid
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Pfizer bets on CD47 blockade in cancer with $2.3B Trillium bid
Aug. 23, 2021
By
Cormac Sheridan
No Comments
Pfizer Inc. has turned up the temperature in the already hot CD47 inhibitor space by offering $18.50 per share or $2.26 billion cash to acquire Trillium Therapeutics Inc., a biotech with two clinical-stage CD47 inhibitors.
BioWorld
Deals and M&A
Acquisition
Cancer